Synthesis, in vitro antiproliferative activities, and Chk1 inhibitory properties of dipyrrolo[3,4-a:3,4-c]carbazole-triones

Tetrahedron

Volumn 62, Issue 48, 2006, Pages 11136-11144

  Conchon, Elisabeth ^a   Anizon, Fabrice ^a   Golsteyn, Roy M ^b   Léonce, Stéphane ^b   Pfeiffer, Bruno ^b   Prudhomme, Michelle ^a  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

Antitumor agents; Chk1 inhibitors; Dipyrrolo 3,4 a:3,4 c carbazole 1,4,6 trione; Dipyrrolo 3,4 a:3,4 c carbazole 3,4,6 trione; Granulatimide

Indexed keywords

10 BENZYLOXY 2H,5H,7H 1,3,3A,3B,4,6,6A,11C OCTAHYDRODIPYRROLO[3,4 A:3,4 C]CARBAZOLE 3,4,6 TRIONE; 10 BENZYLOXY 2H,5H,7H 1,3,4,6 TETRAHYDRODIPYRROLO[3,4 A:3,4 C]CARBAZOLE 1,4,6 TRIONE; 10 HYDROXY 2H,5H,7H 1,3,3A,3B,4,6,6A,11C OCTAHYDRODIPYRROLO[3,4 A:3,4 C]CARBAZOLE 1,4,6 TRIONE; 10 HYDROXY 2H,5H,7H 1,3,4,6 TETRAHYDRODIPYRROLO[3,4 A:3,4 C]CARBAZOLE 1,4,6 TRIONE; 10 METHYL 2H,5H,7H 1,3,3A,3B,4,6,6A,11C OCTAHYDRODIPYRROLO[3,4 A:3,4 C]CARBAZOLE 1,4,6 TRIONE; 10 METHYL 2H,5H,7H 1,3,4,6 TETRAHYDRODIPYRROLO[3,4 A:3,4 C]CARBAZOLE 1,4,6 TRIONE; 10 METHYL 2H,5H,7H 1,3,4,6 TETRAHYDRODIPYRROLO[3,4 A:3,4 C]CARBAZOLE 3,4,6 TRIONE; 2H,5H,7H 1,3,4,6 TETRAHYDRODIPYRROLO[3,4 A:3,4 C]CARBAZOLE 1,4,6 TRIONE; 2H,5H,7H 1,3,4,6 TETRAHYDRODIPYRROLO[3,4 A:3,4 C]CARBAZOLE 3,4,6 TRIONE; 3 (1H INDOL 3 YL) 1H 2,5 DIHYDROPYRROL 2 ONE; 3 (1H INDOL 3 YL) 1H 5 HYDROXY 2,5 DIHYDROPYRROL 2 ONE; 3 (1H INDOL 3 YL) 1H PYRROLE; 3 (5 BENZYLOXY 1H INDOL 3 YL) 1H 2,5 DIHYDROPYRROL 2 ONE; 3 (5 BENZYLOXY 1H INDOL 3 YL) 1H 5 HYDROXY 2,5 DIHYDROPYRROL 2 ONE; 3 (5 HYDROXY 1H INDOL 3 YL) 1H 2,5 DIHYDROPYRROL 2 ONE; 3 (5 METHYL 1H INDOL 3 YL) 1H 2,5 DIHYDROPYRROL 2 ONE; 3 (5 METHYL 1H INDOL 3 YL) 1H 5 HYDROXY 2,5 DIHYDROPYRROL 2 ONE; 3 (5 METHYL 1H INDOL 3 YL) 1H PYRROLE; 4 (1H INDOL 3 YL) 1H 2,5 DIHYDROPYRROL 2 ONE; 4 (1H INDOL 3 YL) 1H 5 HYDROXY 2,5 DIHYDROPYRROL 2 ONE; 4 (5 BENZYLOXY 1H INDOL 3 YL) 1H 2,5 DIHYDROPYRROL 2 ONE; 4 (5 BENZYLOXY 1H INDOL 3 YL) 1H 5 HYDROXY 2,5 DIHYDROPYRROL 2 ONE; 4 (5 HYDROXY 1H INDOL 3 YL) 1H 5 HYDROXY 2,5 DIHYDROPYRROL 2 ONE; 4 (5 METHYL 1H INDOL 3 YL) 1H 2,5 DIHYDROPYRROL 2 ONE; 4 (5 METHYL 1H INDOL 3 YL) 1H 5 HYDROXY 2,5 DIHYDROPYRROL 2 ONE; CARBAZOLE DERIVATIVE; CHECKPOINT KINASE 1; PHOSPHOTRANSFERASE INHIBITOR; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

MURINAE;

EID: 33750003936     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tet.2006.09.027     Document Type: Article

References (29)

1. Prudhomme M. Curr. Pharm. Des. 3 (1997) 265-290
2. Prudhomme M. Curr. Med. Chem.: Anti-Cancer Agents 4 (2004) 509-521
3. Knölker H.-J., and Reddy K.R. Chem. Rev. 102 (2002) 4303-4427
4. Anderson H.J., Andersen R.J., and Roberge M. In: Meijer L., Jézéquel A., and Roberge M. (Eds). Progress in the Cell Cycle Research Vol. 5 (2003), Editions, Roscoff, France 423-430
5. Roberge M., Berlinck R.G.S., Xu L., Anderson H.J., Lim L.Y., Curman D., Stringer C.M., Friend S.H., Davies P., Vincent I., Haggarty S.J., Kelly M.T., Britton R., Piers E., and Andersen R.J. Cancer Res. 58 (1998) 5701-5706
6. Busby E.C., Leistritz R.T., Karnitz L.M., and Sarkaria J.N. Cancer Res. 60 (2000) 2108-2112
7. Jackson J.R., Gilmartin A., Imburgia C., Winkler J.D., Marshall L.A., and Roshak A. Cancer Res. 60 (2000) 566-572
8. Vermeulen K., Van Bockstaele D.R., and Berneman Z.N. Cell Prolif. 36 (2003) 131-149
9. Cuddihy A.R., and O'Connell M.J. Cytology 222 (2003) 99-140
10. McGowan C.H. Mutat. Res. 532 (2003) 75-84
11. Bartek J., and Lukas J. Cancer Cell 3 (2003) 421-429
12. Carrassa L., Broggini M., Erba E., and Damia G. Cell Cycle 3 (2004) 1177-1181
13. Zhao B., Bower M.J., McDevitt P.J., Zhao H., Davis S.T., Johanson K.O., Green S.M., Concha N.O., and Zhou B.B.S. J. Biol. Chem. 277 (2002) 46609-46615
14. Jiang X., Zhao B., Britton R., Lim L.Y., Leong D., Sanghera J.S., Zhou B.-B.S., Piers E., Andersen R.J., and Roberge M. Mol. Cancer Ther. 3 (2004) 1221-1227
15. Berlinck R.G.S., Britton R., Piers E., Lim L., Roberge M., Moreira da Rocha R., and Andersen R.J. J. Org. Chem. 63 (1998) 9850-9856
16. Piers E., Britton R., and Andersen R.J. J. Org. Chem. 65 (2000) 530-535
17. Yoshida T., Nishiyachi M., Nakashima N., Murase M., and Kotani E. Chem. Pharm. Bull. 50 (2002) 872-876
18. Yoshida T., Nishiyachi M., Nakashima N., Murase M., and Kotani E. Chem. Pharm. Bull. 51 (2003) 209-214
19. Terpin A., Winklhofer C., Schumann S., and Steglich W. Tetrahedron 54 (1998) 1745-1752
20. Hugon B., Pfeiffer B., Renard P., and Prudhomme M. Tetrahedron Lett. 44 (2003) 3927-3930
21. Hugon B., Pfeiffer B., Renard P., and Prudhomme M. Tetrahedron Lett. 44 (2003) 4607-4611
22. Hugon B., Pfeiffer B., Renard P., and Prudhomme M. Tetrahedron Lett. 44 (2003) 3935-3937
23. Hénon H., Messaoudi S., Hugon B., Anizon F., Pfeiffer B., and Prudhomme M. Tetrahedron 61 (2005) 5599-5614
24. Hénon H., Anizon F., Kucharczyk N., Loynel A., Casara P., Pfeiffer B., and Prudhomme M. Synthesis (2006) 711-715
25. Mase N., Nishi T., Hiyoshi M., Ichihara K., Bessho J., Yoda H., and Takabe K. J. Chem. Soc., Perkin Trans. 1 (2002) 707-709
26. Bergman J., Janosik T., Koch E., and Pelcman B. J. Chem. Soc., Perkin Trans. 1 (2000) 2615-2621
27. Hénon H., Anizon F., Golsteyn R.M., Léonce S., Hofmann R., Pfeiffer B., and Prudhomme M. Bioorg. Med. Chem. 14 (2006) 3825-3834
28. Davies S.P., Reddy H., Caivano M., and Cohen P. Biochem. J. 351 (2000) 95-105
29. Léonce S., Pérez V., Casabianca-Pignède M.R., Anstett M., Bisagni E., and Atassi G. Invest. New Drugs 14 (1996) 169-180